Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy

Figure 2 Distributions of the 1^st phase decline (A and C) and the 2^nd phase slope (B and D) and their correlation with virological end-points given per HCV genotype and dosing schedule for non-cirrhotic patients (A and B) and each HCV genotype and histological status (C and D). As in previous studies a 2^nd phase decline slope slower than 0.3 log IU/mL per week is predictive of non-SVR (horizontal dashed line in B and D).